BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/10/2022 5:40:20 AM | Browse: 285 | Download: 483
 |
Received |
|
2021-11-04 11:27 |
|
Peer-Review Started |
|
2021-11-04 11:28 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-26 21:26 |
|
Revised |
|
2022-01-09 03:21 |
|
Second Decision |
|
2022-04-27 02:38 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-04-28 02:07 |
|
Articles in Press |
|
2022-04-28 02:07 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-04-15 10:53 |
|
Typeset the Manuscript |
|
2022-05-26 08:30 |
|
Publish the Manuscript Online |
|
2022-06-10 05:40 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Future therapies for pancreatic carcinoma: Insights into cancer precision medicine
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Qiu-Yu Jiang, Zhi-Xue Chen, Si Zhang and Ru-Yi Xue |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ru-Yi Xue, MD, PhD, Associate Chief Physician, Department of Gastroenterology and Hepatology, Zhongshan Hospital, Shanghai Institute of Liver Disease, Fudan University, No. 180 Fenglin Road, Shanghai 200032, China. xue.ruyi@zs-hospital.sh.cn |
| Key Words |
Pancreatic carcinoma; Immunotherapy; Chemotherapy; Radiochemotherapy |
| Core Tip |
For the treatment of pancreatic carcinoma (PC), although surgery with adjuvant chemotherapy or chemoradiotherapy remains the gold standard for most patients, attention needs to be aroused to the immunotherapy and other hotspots. In addition to programmed cell death protein 1/programmed cell death ligand 1, we thought that immunotherapies such as agonistic CD40, adoptive T cell therapy, myeloid-targeted therapies, stroma-targeted therapies, multiple immune-modulatory agents, and other treatments such as small-molecule inhibitors, antibodies, or viruses targeting tumors, as well as gene editing techniques, may help improve the prognosis of patients with PC in the future. |
| Publish Date |
2022-06-10 05:40 |
| Citation |
Jiang QY, Chen ZX, Zhang S, Xue RY. Future therapies for pancreatic carcinoma: Insights into cancer precision medicine. World J Gastroenterol 2022; 28(22): 2523-2526 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i22/2523.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i22.2523 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
